Aon | January 28, 2021
Aon Group, a main worldwide expert administrations firm giving a wide scope of danger, retirement and wellbeing arrangements, and Elements of Genius (EoG), a worldwide innovator in the voice-empowered Artificial Intelligence, announced an essential joint effort to enable Aon's Goodme stage with a unique voice chatbots. This union will permit the two organizations to lead in AI controlled healthcare administrations conveyance which offers tremendous advantages and simplicity to suppliers and patients in the United States and Europe.
EoG is one of the quickest developing secretly held AI organizations in the U.S. also, a breakaway chief in the field of "sincerely mindful" man-made reasoning. EoG's VoxAI programming can foresee, on a passionate level, the necessities of shoppers and guide them to the best arrangement utilizing a voice-based application across any gadget. In contrast to other voice collaborators, VoxAI makes a customized voice association that reproduces normal discussion. Incorporating the mastery of the two groups will drive the conveyance of genuinely unparalleled items and administrations that ought to improve care, accommodation and results.
"Aon is excited to partner with Elements of Genius and to see the Goodme platform lead the way in providing an "Amazon-like" experience in healthcare. We have developed the Goodme platform to satisfy the unmet needs of physicians and consumers." said Mr. Enrico Vanin, CEO of Aon S.p.A. and of Aon Advisory and Solutions S.r.l.. "With Elements of Genius' VoxAI software, we are taking Goodme to the next level with the ability to understand emotions and dynamically respond to those hidden needs. Since emotions guide 90% of human decisions, we believe this technology will create a superior personalized health experience and unearth insights that will contribute to better decisions and better care.
Jon Ramaci, Founder & CEO of Elements of Genius, adds, "This is an amazing opportunity to have transformative impact at scale. With Aon and EoG, all of the pieces are in place to deliver meaningful solutions that empower physicians and patients to have a radically better healthcare experience, which will result in better outcomes. Combining the user-friendly Goodme platform with a voice-based user interface that deeply understands patient needs by reading emotions provides a whole new way of better detecting and addressing health needs.
Enrico Vanin, CEO of Aon S.p.A. and of Aon Advisory and Solutions S.r.l., states "this alliance brings exponential value to our shared clients. We've managed to combine the best AI voice-based software development firm with the best health solutions firm, and that's a powerful combination. The products from that collaboration will be unmatchable."
Joining these market chiefs on propelling consideration by making a less complex, customized, prescient experience for patients and suppliers is required to deliver high effect arrangements that will catalyze extraordinary change in healthcare around the world.
Aon is the leading provider in Italy of risk management and human resource consulting and insurance and reinsurance brokerage services. Aon Italia is the Italian branch of Aon Plc, the parent company listed on the NYSE and based in London. The company operates in over 150 countries with 50,000 employees. Aon, which has always been attentive to innovation in the dynamic insurance market, provides support and specific skills in defining strategies that enable the various corporate risks to be managed and controlled.
About Elements of Genius, Inc.
Elements of Genius is a global leader in voice-enabled systems and artificial intelligence developing products and services across sectors including healthcare, retail, hospitality, insurance and banking. Its patented hardware and software enable development of custom development voice-enabled solutions that drastically improve the customer experience and collects valuable customer intelligence.
Modern Healthcare | October 19, 2021
Modern Healthcare, a Crain Communications brand, is pleased to announce the launch of Digital Health Business & Technology, a digital media brand that covers the latest news, data and insights on all aspects of digital healthcare technologies, from hardware, software products and services to finance, investment and mergers and acquisitions activity.
The new digital brand leverages the editorial expertise of Modern Healthcare, an industry-leading provider of healthcare business news for more than 45 years, as well as 10 years of global digital health deal information and analysis acquired from Mercom Capital's Digital Health Business in June 2021. The resulting product portfolio will include:
The Digital Health Business and Technology website (DigitalHealthBusinessandTechnology.com), featuring news coverage, a research and data center and quarterly M&A reports
The Digital Health Deal and Digital Health Intel weekly e-newsletters
A Digital Health Alert for breaking industry news
For a limited time, healthcare executives in senior leadership roles in operations, financial and clinical management, information technology and related areas; entrepreneurs and senior leaders within digital health solution provider companies; investment firms, private and institutional investors (commercial banks, mutual funds, etc.), venture capitalists; private equity firms and angel investors, are invited to register for trial access to online content and e-newsletters from Digital Health Business & Technology.
"Digital Health Business & Technology offerings will serve the needs of the entire digital health ecosystem, enabling healthcare executives, entrepreneurs, business leaders and investors to determine how best to leverage digital health solutions for improved outcomes, accelerated innovation and greater business growth," said Fawn Lopez, publisher of Modern Healthcare.
"Our digital health portfolio will serve the information needs of healthcare executives who are seeking to understand the strategic business value of the latest digital health technology solutions to their operations, along with technology professionals at provider and clinical organizations who evaluate and determine which technology solutions are the right fit for their digital health strategies, and investors who track deals, IPOs and M&A activity to identify trends for future investment in digital health companies."
Jon Morton, general manager of Digital Health Business & Technology
According to McKinsey & Company, in 2019, digital health represented a global market worth approximately $350 billion. All digital health value pools are expected to grow by at least 8% annually through 2024, leading to an estimated market size of at least $600 billion.
About Modern Healthcare, published by Crain Communications Inc
Modern Healthcare is the industry's leading source of healthcare business and policy news, research and information, reporting on important healthcare events and trends as they happen on the web, in newsletters and alerts, the MH print magazine and events. Modern Healthcare's unbiased approach and commitment to fair reporting provides news and information that you can trust. Delivering in depth analysis, readers rely on Modern Healthcare to provide the insight into what is happening next, how it will impact organizations and what can be done to ensure success in an ever-changing healthcare landscape.
NVIDIA | July 07, 2021
NVIDIA today officially launched Cambridge-1, the United Kingdom’s most powerful supercomputer, which will enable top scientists and healthcare experts to use the powerful combination of AI and simulation to accelerate the digital biology revolution and bolster the country’s world-leading life sciences industry.
Dedicated to advancing healthcare, Cambridge-1 represents a $100 million investment by NVIDIA. Its first projects with AstraZeneca, GSK, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London and Oxford Nanopore Technologies include developing a deeper understanding of brain diseases like dementia, using AI to design new drugs and improving the accuracy of finding disease-causing variations in human genomes.
Cambridge-1 brings together decades of NVIDIA’s work in accelerated computing, AI and life sciences, where NVIDIA Clara™ and AI frameworks are optimized to take advantage of the entire system for large-scale research. An NVIDIA DGX SuperPOD™ supercomputing cluster, it ranks among the world’s top 50 fastest computers and is powered by 100 percent renewable energy.
“Cambridge-1 will empower world-leading researchers in business and academia with the ability to perform their life’s work on the U.K.’s most powerful supercomputer, unlocking clues to disease and treatments at a scale and speed previously impossible in the U.K.,” said Jensen Huang, founder and CEO of NVIDIA. “The discoveries developed on Cambridge-1 will take shape in the U.K., but the impact will be global, driving groundbreaking research that has the potential to benefit millions around the world.”
Cambridge-1 builds on the U.K.’s status as a global leader in life sciences, technology and AI by providing advanced infrastructure for current and future generations to carry out groundbreaking research within the country.
According to a report by Frontier Economics, an economics consulting firm, Cambridge-1 has the potential to create an estimated value of £600 million (about $825 million) over the next 10 years.
AstraZeneca: Transforming Drug Discovery with AI
NVIDIA is collaborating with AstraZeneca to fuel faster drug discoveries by creating a transformer-based generative AI model for chemical structures. Transformer-based neural network architectures, which have become available only in the last several years, allow researchers to leverage massive datasets using self-supervised training methods, avoiding the need for manually labeled examples during pre-training.
The MegaMolBART drug discovery model is being used in reaction prediction, molecular optimization and de novo molecular generation and will optimize the drug development process. It is based on AstraZeneca’s MolBART transformer model and is being trained on the ZINC chemical compound database — using NVIDIA’s Megatron framework to enable massively scaled-out training on supercomputing infrastructure. This open-source model will be available to researchers and developers in the NVIDIA NGC™ software catalog.
NVIDIA and AstraZeneca have a separate project on Cambridge-1 focused on the use of AI in digital pathology. In digital pathology, significant time and money are spent annotating whole slide images of tissue samples, to aid the search for new insights. By using unsupervised AI algorithms trained on thousands of images, it is possible to remove the process of annotating while simultaneously finding potential imaging features that correlate with drug response.
“Training AI algorithms on whole slide images is challenging in part due to the size of the images,” said Lindsay Edwards, vice president of Data Science and AI, Respiratory and Immunology, BioPharmaceuticals R&D at AstraZeneca. “Working with NVIDIA on Cambridge-1 enables us to scale our current work and develop new methodologies advancing the use of AI in digital pathology.”
GSK: Steering Great Science with Partners for Patients
GSK’s research and development approach includes a focus on genetically validated targets, which are twice as likely to become medicines and now make up more than 70 percent of its research pipeline. To maximize the potential of these insights, GSK has built state-of-the-art capabilities at the intersection of human genetics, functional genomics, and artificial intelligence and machine learning.
“Advanced technologies are core to GSK’s R&D approach and help to unlock the potential of large, complex data through predictive modeling at new levels of speed, precision and scale,” said Dr. Kim Branson, senior vice president and global head of AI-ML at GSK. “We are pleased to have the opportunity to partner with NVIDIA to deliver on GSK’s drug discovery ambition and contribute to the U.K.’s rich life sciences ecosystem — both aims that have patient benefit at the centre.”
Working with partners at the cutting edge of genetics, genomics and AI/ML can ultimately help GSK predict more about human health, and develop better medicines that are twice as likely to succeed in the clinic and go on to become approved therapies that benefit patients. Access to Cambridge-1 will contribute additional computational power and state-of-the-art AI technology to GSK’s drug discovery process.
King’s College London & Guy’s and St Thomas’ NHS Foundation Trust: AI-Generated Synthetic Brain Data
King’s College London and Guy’s and St Thomas’ NHS Foundation Trust are using Cambridge-1 to teach AI models to generate synthetic brain images by learning from tens of thousands of MRI brain scans, from various ages and diseases. The ultimate goal is to use this synthetic data model to gain a better understanding of diseases like dementia, stroke, brain cancer and multiple sclerosis and enable earlier diagnosis and treatment.
As this AI synthetic brain model can generate an infinite amount of never-seen brain images with chosen characteristics (age, disease, etc.), it will allow a better and more nuanced understanding of what diseases look like, possibly enabling an earlier and more accurate diagnosis.
“Through this partnership, we will be able to use a scale of computational power that is unprecedented in healthcare research,” said Professor Sebastien Ourselin, head of the School of Biomedical Engineering & Imaging Sciences at King’s College London. “It will be truly transformational for the health and treatment of patients.”
This research leverages several of the U.K.’s world-leading healthcare resources through close collaboration with the National Health Service and the UK Biobank, one of the richest biomedical databases in the world. King’s College London intends to share this synthetic data model with the greater research and startup community.
“The power of artificial intelligence in healthcare will help to speed up diagnosis for patients, improve services such as breast cancer screening, and support the way that we risk assess and prioritize patients according to clinical need,” said Professor Ian Abbs, chief executive officer of Guy’s and St Thomas’ NHS Foundation Trust. “We are excited about our involvement in the Cambridge-1 data center as it will enable us to be amongst the first to benefit from these new AI capabilities — using the very latest technology to benefit our patients, as well as manage precious resources more efficiently.”
Oxford Nanopore: Scalable, Real-Time Genomics
Oxford Nanopore Technologies’ long-read sequencing technology is being used in more than 100 countries to gain genomic insights across a breadth of research areas — from human and plant health to environmental monitoring and antimicrobial resistance.
Oxford Nanopore deploys NVIDIA technology in a variety of genomic sequencing platforms to develop AI tools that improve the speed and accuracy of genomic analysis. With access to Cambridge-1, Oxford Nanopore will be able to carry out tasks relating to algorithm improvement in hours rather than days. These improved algorithms will ensure improved genomic accuracy for greater insights and quicker turnaround times in scientists’ hands.
“Harnessing the power of Cambridge-1 will help us further speed up our algorithm development to support powerful, accurate genomic analysis,” said Rosemary Sinclair Dokos, vice president of Product and Programme Management at Oxford Nanopore. “This will in turn enable the scientists using our technology on the ground to gain more insights than ever before, across a breadth of research areas.”
Cambridge-1 is the first NVIDIA supercomputer designed and built for external research access. The company will collaborate with researchers to make much of this work available to the greater scientific community.
NVIDIA’s (NASDAQ: NVDA) invention of the GPU in 1999 sparked the growth of the PC gaming market and has redefined modern computer graphics, high performance computing and artificial intelligence. The company’s pioneering work in accelerated computing and AI is reshaping trillion-dollar industries, such as transportation, healthcare and manufacturing, and fueling the growth of many others.